Prostate-specifi c antigen tests and prostate cancer screening: An update for primary care physicians

Canadian Journal of Urology

Volumn 17, Issue , 2010, Pages 18-25

  Kell, John S ^a  

^a TORONTO EAST GENERAL HOSPITAL   (Canada)

Author keywords

Early cancer detection; Prostate adenocarcinoma; Prostatespecific antigen; Review

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; BLOOD; CANADA; CLINICAL PRACTICE; EARLY DIAGNOSIS; GENERAL PRACTITIONER; HEALTH PERSONNEL ATTITUDE; HUMAN; MALE; MASS SCREENING; METHODOLOGY; MIDDLE AGED; PREVALENCE; PRIMARY HEALTH CARE; PROGNOSIS; PROSTATE TUMOR; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; SURVIVAL RATE;

AGE DISTRIBUTION; AGED; ATTITUDE OF HEALTH PERSONNEL; CANADA; EARLY DETECTION OF CANCER; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY; PREVALENCE; PRIMARY HEALTH CARE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 77952478579     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Laspina M, Haas GP. Update on the diagnosis and management of prostate cancer. Can J Urol 2008;15(Suppl 1):3-13.
2. Gittens PR, Lallas CD, Pe Ml, Perkel R, Folia C, Gomella LG. Uropharmacology for the primary care physician. Can J Urol 2008;15(Suppl 1):78-91.
3. Andriole GL, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld, JL, Yokochi LA, Crawford ED, OâBrien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360(13):1310-1319.
4. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maatanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328.
5. American Urology Association. Prostate-specifi c antigen best practice statement: 2009 update. Available: www.auanet.org/ content/guidelines-and-quality-care/clinical-guidelines/mainreports/ psa09.pdf.
6. Kolata G. Prostate test found to save few lives. The New York Times 2009; March 18.
7. Grave HC, Sensabaugh GF, Blake ET. Postcoital detection of a male-specifi c semen protein. Application to the investigation of rape. N Engl J Med 1985;312(6):338-343.
8. Lilja H. Structure and function of prostatic and seminal vesiclesecreted proteins involved in the gelation and liquefaction of human semen. Scand J Clin Lab Invest 1988;191(Suppl): 13-20.
9. Kuriyama M, Wang MC, Papsidero LD, Killan CS, Shimano T, Valenzuela L, Murphy GP, Chu TM. Quantitation of prostatespecifi c antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980;40(12):4658-4662.
10. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324(17):1156-1161.
11. Goroll AH, Mulley AG. Primary Care Medicine. 6th ed. Philadelphia. Lipincott; 2009:16-20.
12. Gates TJ. Screening for cancer: evaluating the evidence. Am Fam Physician 2001;63(3):513-522.
13. Canadian Cancer Society. Canadian Cancer Statistics 2009. www.cancer.ca.
14. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993;150(2 Pt 1):379-385.
15. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP. High grade prostatic intra epithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8(3):439-443.
16. Brawer MK. Prostate-specifi c antigen: current status. CA Cancer J Clin 1999;49(5):264-281.
17. Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessala RL, Lange PH. Screening for prostatic carcinoma with prostate specifi c antigen. J Urol 1992;147(3 Pt 2):841-845.
18. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Klejnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006; 175(5):1605-1612.
19. Levine MA, Ittman M, Melamed J, Lepor H. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 1998;159(2): 471-475.
20. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Miniasen LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specifi c antigen level
21. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996;276(16):1309-1315.
22. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA Jr, Thompson IM. Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implication for prostate cancer detection and chemoprevention. Cancer Prev Res 2008;1(3):167-173.
23. Ochial A, Troncoso P, Babaian RJ. The relationship between serum prostate specifi c antigen level and tumor volume persists in the current era. J Urol 2007;177(3):903-906.
24. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostatespecific antigen concentration. Urol Clin North Am 1997; 24(2):283-291.
25. Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merril RM, Kaplan RS. Cancer surveillance series: interpreting trends in prostate cancerpart I: evidence of the effects of screening in the recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 1999;91(12):1017-1024.
26. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specifi c antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy patients. J Urol 1989;141(5):1076-1083.
27. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Postoperative serum prostate specifi c antigen levels between 2 and 22 ng./ml correlate poorly with post-radical prostatectomy cancer morphology: prostate specifi c antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002;167(1):103-111.
28. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL et al. Comparison of digital rectal examination and serum prostate specifi c antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151(5):1283-1290.
29. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO. Natural history of early, localized prostate cancer. JAMA 2004;291(22):2713-2719.
30. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specifi c antigen screening: 1986-2005. J Natl Cancer Inst 2009;101(19): 1325-1329.
31. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specifi c antigen in a community-based population of healthy men. Establishment of age-specifi c ranges. JAMA 1993;270(7):860-864.